METABOLIK ASSOTSIRLANGAN STEATOGEPATITLI BEMORLARNING DIAGNOSTIKASINI OPTIMALLASHTIRISH BO`YICHA ADABIYOTLAR SHARHIv
Keywords:
MASLD, MASH, steatogepatit, jigar fibrozi, invaziv bo‘lmagan testlar, FIB-4, elastografiya, MRI-PDFF, MRE, ELF, PRO-C3, diagnostik algoritm.Abstract
Metabolik assotsiatsiyalangan steatogepatit (MASH) metabolik disfunktsiya bilan bog‘liq steatotik jigar kasalligi (MASLD) spektrining faol va progressiv shakli bo‘lib, fibroz rivojlanishi va sirroz hamda gepatosellyulyar karsinoma xavfi bilan bevosita aloqador. So‘nggi yillarda atamalar va diagnostik yondashuvlar sezilarli yangilandi: klinik amaliyotda invaziv bo‘lmagan testlar (NIT) yordamida “at-risk” (kamida F2 fibroz) bemorlarni erta aniqlash, ularni to‘g‘ri yo‘naltirish hamda monitoring qilish diagnostikaning asosiy maqsadiga aylandi. Ushbu adabiyotlar sharhida MASH patogenezi va klinik fenotiplari, laborator ko‘rsatkichlar va skorlash tizimlari (FIB-4, NFS), elastografiya (VCTE), MR asosidagi texnologiyalar (MRI-PDFF, MRE), zardob biomarkerlari (ELF, PRO-C3) hamda kombinatsiyalangan algoritmlar bo‘yicha dalillar tahlil qilinadi. Shuningdek, diagnostikani optimallashtirish uchun bosqichma-bosqich (risk-stratifikatsiya → ikkilamchi baholash → ixtisoslashgan yo‘naltirish) yondashuvning amaliy modeli taklif etiladi.
References
Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F. va boshq. A multisociety Delphi consensus statement on new fatty liver disease nomenclature // Hepatology. – 2023. – Vol. 78, № 6. – P. 1966–1986. – DOI: 10.1097/HEP.0000000000000520.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) // Journal of Hepatology. – 2024. – Vol. 81, № 3. – P. 492–542. – DOI: 10.1016/j.jhep.2024.04.031.
Rinella M.E., Neuschwander-Tetri B.A., Caldwell S.H. va boshq. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. – 2023. – Vol. 77, № 5. – P. 1797–1835. – DOI: 10.1097/HEP.0000000000000323.
Castera L., Rinella M.E., Tsochatzis E.A. Noninvasive Assessment of Liver Fibrosis // The New England Journal of Medicine. – 2025. – Vol. 393, № 17. – P. 1715–1729. – DOI: 10.1056/NEJMra2403308.
Younossi Z.M., Golabi P., de Avila L. va boshq. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review // Hepatology. – 2023. – Vol. 77, № 4. – P. 1335–1347. – DOI: 10.1097/HEP.0000000000000004.
Feng G., Wang X. va boshq. Global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) using Global Burden of Disease data (2010–2021) // JHEP Reports. – 2025. – (maqola ma’lumotlari bo‘yicha).
Angulo P., Hui J.M., Marchesini G. va boshq. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD // Hepatology. – 2007. – Vol. 45, № 4. – P. 846–854. – DOI: 10.1002/hep.21496.
Sterling R.K., Lissen E., Clumeck N. va boshq. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (FIB-4) // Hepatology. – 2006. – Vol. 43, № 6. – P. 1317–1325. – DOI: 10.1002/hep.21178.
Karlas T., Petroff D., Sasso M. va boshq. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis // Journal of Hepatology. – 2017. – Vol. 66, № 5. – P. 1022–1030. – DOI: 10.1016/j.jhep.2016.12.022.
Vali Y., Lee J., Boursier J. va boshq. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in NAFLD: a systematic review and meta-analysis // Journal of Hepatology. – 2020. – (son/raqamlar bo‘yicha). – DOI: 10.1016/S0168-8278(20)30198-7.
Boyle M., Tiniakos D., Schattenberg J.M. va boshq. Performance of the PRO-C3 collagen neo-epitope biomarker in the diagnosis of advanced fibrosis in NAFLD // Journal of Hepatology. – 2019. – Vol. 71. – (betlar).
Mózes F.E., Lee J.A., Selvaraj E.A. va boshq. Performance of non-invasive tests and histology for the prediction of clinical outcomes in NAFLD (IPD meta-analysis) // The Lancet Gastroenterology & Hepatology. – 2023. – (son/raqamlar bo‘yicha).
Woreta T.A., Liu Y., Dizechi S. va boshq. Validation of the accuracy of the FAST score for identifying patients with at-risk NASH // (PMC manbasi bo‘yicha). – 2022.
Stine J.G., Munaganuru N., Barnard A. va boshq. Change in MRI-PDFF and histologic response in patients with NASH: a systematic review and meta-analysis // Clinical Gastroenterology and Hepatology. – 2021. – (son/raqamlar).
U.S. Food and Drug Administration (FDA). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (Rezdiffra/resmetirom) // Press-announcement. – 14.03.2024.
